Randomized Comparison of Continuous and Intermittent Heparin Infusion During Catheter Ablation of Atrial Fibrillation

Overview

Optimal anticoagulation using heparin with close attention to maintain therapeutic dosing during the procedure is important. Randomized comparison of continuous and intermittent heparin infusion during catheter ablation of Atrial Fibrillation.

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Single (Participant)
  • Study Primary Completion Date: July 2015

Detailed Description

Intravenous heparin was used during the procedure to prevent catheter-induced thrombosis. heparin is administered during the procedure to achieve recommended activation clotting times (ACT) values, typically >300 seconds to prevent thromboemboli during the procedure. Most of the practitioners was that ACT level should be checked at 30- to 60-minute intervals and then have injected intermittently. intermittent heparin infusion, concentration is great changed because the heparin has 30minutes half-period. researchers postulate that a constant therapeutic concentrations would be beneficial to continuous infusion than intermittent infusion.

Interventions

  • Drug: Continuous heparin infusion
    • continuous group is given an initial intravenous heparin 100u/kg and then maintain heparin infusion during procedural.
  • Drug: Intermittent heparin infusion
    • Intermittent group is given an initial intravenous heparin 100u/kg. Then The ACT is tested every 30min with administration of additional heparin boluses and titration of the heparin drip based on the results and according to the judgment of the operating physician.

Arms, Groups and Cohorts

  • Active Comparator: Continuous heparin infusion group
    • continuous group is given an initial intravenous heparin 100u/kg and then maintain heparin infusion during procedural.
  • Active Comparator: Intermittent heparin infusion group
    • Intermittent group is given an initial intravenous heparin 100u/kg. Then The ACT is tested every 30min with administration of additional heparin boluses and titration of the heparin drip based on the results and according to the judgment of the operating physician.

Clinical Trial Outcome Measures

Primary Measures

  • therapeutic ACT retention rate during procedure
    • Time Frame: 2 years

Participating in This Clinical Trial

Inclusion Criteria

  • Atrial Fibrillation, Radiofrequency catheter ablation scheduled Exclusion Criteria:

  • Clinical trial denied

Gender Eligibility: All

Minimum Age: N/A

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Yong Seog Oh
  • Provider of Information About this Clinical Study
    • Sponsor-Investigator: Yong Seog Oh, Professor – Seoul St. Mary’s Hospital
  • Overall Official(s)
    • Yong Seog Oh, MD, Principal Investigator, Seoul St. Mary’s Hospital

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.